Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2021 07:30 ET | Source: Genocea Biosciences, Inc.

Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy

CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the...
June 04, 2021 09:00 ET | Source: Genocea Biosciences, Inc.

Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021

Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination was 15 months Two of...
April 29, 2021 07:00 ET | Source: Genocea Biosciences, Inc.

Genocea Provides First Quarter 2021 Corporate Update

GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., April ...
April 22, 2021 16:30 ET | Source: Genocea Biosciences, Inc.

Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first...
April 10, 2021 08:30 ET | Source: Genocea Biosciences, Inc.

Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021

Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology may yield new therapeutic targets to address immunotherapy resistance ...
April 06, 2021 16:30 ET | Source: Genocea Biosciences, Inc.

Genocea to Present at the 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
March 02, 2021 16:01 ET | Source: Genocea Biosciences, Inc.

Genocea to Present at the H.C. Wainwright Global Life Sciences Conference

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
February 11, 2021 07:30 ET | Source: Genocea Biosciences, Inc.

Genocea Provides Fourth Quarter 2020 Corporate Update

GEN-011 and GEN-009 clinical trials continue to advance ATLASTM stimulatory antigen and inhibitory antigen (InhibigenTM) identification profiled in Cancer Discovery Announcing SARS-CoV-2 T cell...
February 04, 2021 16:05 ET | Source: Genocea Biosciences, Inc.

Genocea to Host Fourth Quarter 2020 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth...
January 28, 2021 06:00 ET | Source: Genocea Biosciences, Inc.

Genocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS™ Platform

Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigensof anti-tumor T cell responses and excluding Inhibigens™, or neoantigens of pro-tumor T...